Peptide News Digest

#Gland-Pharma

3 stories

Industry · View digest

The Broader Peptide CDMO Consolidation Wave Continues Across August 2026 With Samsung Biologics' Pending $1.8 Billion All-Cash Tender Offer for PolyPeptide Group AG at CHF 44.31 per Share (Prospectus Expected by End of August, Closing Toward End of 2026), the August 11 Gland Pharma and Neuland Laboratories Long-Term Sterile API Manufacturing Partnership in Visakhapatnam India, and Continued Capacity Build-Outs at Bachem, CordenPharma, and AmbioPharm Positioning the Peptide CDMO Industry for the Multi-Billion-Dollar Demand Wave From Semaglutide and Tirzepatide Commercial-Scale API Plus Retatrutide, Amycretin, VK2735, Ribupatide, and Next-Generation Combination Peptide Phase 3 Programs

The broader peptide contract development and manufacturing organization (CDMO) consolidation wave continues across August 2026 with three concurrent developments. First, Samsung Biologics' pending $1.8 billion all-cash tender offer for PolyPeptide Group AG at CHF 44.31 per share (CHF 1.46 billion total equity value, 40% premium to undisturbed share price) advances toward closing: the formal tender offer prospectus is expected to be published by end of August 2026 following Draupnir Holding B.V. (55.65% stake) commitment to tender and PolyPeptide's Board of Directors unanimous recommendation, with closing expected toward end of 2026. Second, Gland Pharma and Neuland Laboratories announced August 11, 2026 a long-term sterile API manufacturing partnership in Visakhapatnam, India, extending India's growing role as a peptide API manufacturing hub. Third, Bachem, CordenPharma, and AmbioPharm continue capacity build-outs. Collective capacity positioning targets the multi-billion-dollar demand wave from semaglutide and tirzepatide commercial-scale API (roughly $17 billion combined active pharmaceutical ingredient market by 2028 per industry estimates) plus retatrutide, amycretin, VK2735, ribupatide, and next-generation combination peptide Phase 3 programs. The consolidation trajectory suggests peptide CDMO capacity concentration among a smaller number of large operators through the end of the decade, with the Samsung acquisition of PolyPeptide as the anchor transaction.

Industry · View digest

Indian Pharmaceutical Stocks Continue Monday August 3 Morning Selloff Following President Trump's Truth Social Post Confirming the Phased Generic-Drug Tariff Schedule (Zero Duty for Two Years Starting August 1 2026, Then 100% Starting August 1 2028, Then 200% Starting August 1 2029); Nifty Pharma Slumps Nearly 2% Making It the Worst-Performing Sectoral Index on the National Stock Exchange in Early Trade With Gland Pharma Leading Losses Down 4.54%, Cipla Down 1.95%, Sun Pharma Down 1.29%, and Dr Reddy's Down Similarly Given India Supplies Approximately 50% of US Generic Prescriptions by Volume

Indian pharmaceutical stocks continued the Monday August 3, 2026 morning selloff following President Trump's Truth Social post confirming the phased generic-drug tariff schedule. The Nifty Pharma index slumped nearly 2% in early trade, making it the worst-performing sectoral index on the National Stock Exchange. Individual stock movements: Gland Pharma led losses down 4.54% to Rs 2,362.5; Cipla, Sun Pharma, and Dr Reddy's Laboratories were among the top early losers at down 1.29-1.95%; Ajanta Pharma, Alkem Laboratories, Mankind Pharma, and Divi's Laboratories all traded 1.3-3% lower. Sensex fell over 400 points; Nifty slipped below 24,150. The tariff schedule: zero duty for two years starting August 1, 2026, then 100% starting August 1, 2028, then 200% starting August 1, 2029. Tariffs on patented and branded medicines (separately governed by Section 232) remain unchanged. India supplies approximately 50% of US generic prescriptions by volume (over 90% of US prescriptions overall are generics). US production costs would be 25-30% higher than in India, making the two-year transition challenging for large-scale onshoring. Analyst commentary suggests creating a viable US generic manufacturing ecosystem would take at least five years.

Regulatory · View digest

President Trump's Truth Social Post Confirms Phased Generic-Drug Tariff Schedule Effective August 1, 2026: Zero Tariff for Two Years Starting Today, Then 100% Tariff Starting August 1, 2028, Then 200% Tariff Starting August 1, 2029; The Policy Is Intended to Restore Generic Pharmaceutical Manufacturing to the United States With Companies That Do Not Build US Manufacturing Facing Steep Tariffs After the Two-Year Transition Period; Indian Pharmaceutical Stocks Slumped Friday and Monday on the Announcement Given India Supplies Approximately 50% of US Generics by Volume and Over 90% of US Prescriptions

President Trump's Truth Social post confirmed the phased generic-drug tariff schedule effective Saturday August 1, 2026: zero tariff for two years starting today, then 100% tariff starting August 1, 2028, then 200% tariff starting August 1, 2029. The policy is intended to restore generic pharmaceutical manufacturing to the United States with companies that do not build US manufacturing facing steep tariffs after the two-year transition period. Analysts have observed that the plan is unlikely to trigger a large-scale shift in production to the US within the proposed two-year transition period, citing high manufacturing costs, long regulatory timelines, and the weak economics of producing low-priced medicines locally; industry executives suggest creating a viable generic manufacturing ecosystem in the US could take at least five years. Indian pharmaceutical stocks slumped Friday and Monday on the announcement. The Nifty Pharma index declined 1.90% to 25,591.8 with all 19 index constituents trading lower. Gland Pharma led losses down 4.83% to Rs 2,362.5, Aurobindo Pharma fell 2.87% to Rs 1,534, and Cipla and Lupin dropped as much as 3%. India supplies approximately 50% of US generics by volume and over 90% of US prescriptions. The generic tariff is separate from the Section 232 patented-drug tariff structure that took effect July 31, 2026 for the 17 named companies in Annex III at 100% duty on patented drugs and APIs (reduced to 20% under onshoring agreements).